Company’s analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error. Calgary, Alberta–(Newsfile Corp. – December 1, 2022) – NurExone Biologic Inc.

“Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request,” said Dr. Lior Shaltiel, CEO of NurExone. “In addition to pursuing our regulatory objective, we are advancing other areas of our business, including securing

Calgary, Alberta–(Newsfile Corp. – November 8, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by

Prior to submission of a New Investigational Drug (IND) application, in September 2022, the Company submitted a request for an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting, which is an informal, non-binding meeting that is offered by the U.S. FDA to companies at an early stage

Exosomes, a key element of ExoTherapy, are derived from stem cells in bio-production processes. The Technion-developed process suggests that shear stress stimulation of stem cells during Three-Dimensional (3D) exosome production yields both increased secretion of exosomes and enhanced exosome potency. NurExone carried out a pilot study of the shear stress

The Company will be participating in the upcoming 2022 Bio-Europe Conference (“Bio-Europe”) in Leipzig, Germany, which commences on October 24th and ends on October 26th. Bio-Europe is regarded as one of Europe’s largest gathering of professionals in the biopharma industry. Over 4000 attendees and more than 2200 companies from around

Calgary, Alberta and Oxford, United Kingdom–(Newsfile Corp. – October 12, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company’s wholly-owned subsidiary, NurExone Biologic Ltd., signed

Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the

NurExone Announces Additional Securities for Debt Settlemen Read More

Under the Letter of Intent, NurExone will explore collaborations with denovoMATRIX to use its advanced screenMATRIX platform to develop specialized coatings for NurExone’s cell carriers for exosome production in order to optimize the manufacturing processes of the non-invasive NurExone’s ExoTherapy. The primary aim of the collaboration is to develop a